110 related articles for article (PubMed ID: 14729646)
1. Development of a cancer-targeted tissue-specific promoter system.
Fukazawa T; Maeda Y; Sladek FM; Owen-Schaub LB
Cancer Res; 2004 Jan; 64(1):363-9. PubMed ID: 14729646
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system.
Fukazawa T; Maeda Y; Durbin ML; Nakai T; Matsuoka J; Tanaka H; Naomoto Y; Tanaka N
Mol Cancer Ther; 2007 Jan; 6(1):244-52. PubMed ID: 17237283
[TBL] [Abstract][Full Text] [Related]
3. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells.
Tanyi JL; Lapushin R; Eder A; Auersperg N; Tabassam FH; Roth JA; Gu J; Fang B; Mills GB; Wolf J
Gynecol Oncol; 2002 Jun; 85(3):451-8. PubMed ID: 12051873
[TBL] [Abstract][Full Text] [Related]
4. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
5. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter.
Komata T; Koga S; Hirohata S; Takakura M; Germano IM; Inoue M; Kyo S; Kondo S; Kondo Y
Int J Oncol; 2001 Nov; 19(5):1015-20. PubMed ID: 11605003
[TBL] [Abstract][Full Text] [Related]
6. Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.
Bilsland AE; Fletcher-Monaghan A; Keith WN
Neoplasia; 2005 Nov; 7(11):1020-9. PubMed ID: 16331888
[TBL] [Abstract][Full Text] [Related]
7. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter.
Berry NB; Cho YM; Harrington MA; Williams SD; Foley J; Nephew KP
Gynecol Oncol; 2004 Mar; 92(3):896-904. PubMed ID: 14984958
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line.
Song JS; Kim HP; Yoon WS; Lee KW; Kim MH; Kim KT; Kim HS; Kim YT
Biosci Biotechnol Biochem; 2003 Nov; 67(11):2344-50. PubMed ID: 14646192
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific gene therapy.
Lo HW; Day CP; Hung MC
Adv Genet; 2005; 54():235-55. PubMed ID: 16096014
[TBL] [Abstract][Full Text] [Related]
11. Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter system.
Fukazawa T; Maeda Y; Matsuoka J; Tanaka N; Tanaka H; Durbin ML; Naomoto Y
Int J Cancer; 2009 Oct; 125(8):1975-84. PubMed ID: 19598260
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy.
Murofushi Y; Nagano S; Kamizono J; Takahashi T; Fujiwara H; Komiya S; Matsuishi T; Kosai K
Int J Oncol; 2006 Sep; 29(3):681-8. PubMed ID: 16865285
[TBL] [Abstract][Full Text] [Related]
13. Modification of the hTERT promoter by heat shock elements enhances the efficiency and specificity of cancer targeted gene therapy.
Wang X; Zhou P; Sun X; Wei G; Zhang L; Wang H; Yao J; Jia P; Zheng J
Int J Hyperthermia; 2016 May; 32(3):244-53. PubMed ID: 26981638
[TBL] [Abstract][Full Text] [Related]
14. Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer.
Wang L; Soria JC; Chang YS; Lee HY; Wei Q; Mao L
Oncogene; 2003 Oct; 22(46):7123-9. PubMed ID: 14562040
[TBL] [Abstract][Full Text] [Related]
15. [Cloning of human telomerase reverse transcriptase promoter for targeted cancer therapy].
Li F; Tan XH; Peng XJ; Cai HB; Hu DR
Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):207-11. PubMed ID: 15699008
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer.
Song JS
Biosci Biotechnol Biochem; 2005 Jan; 69(1):56-62. PubMed ID: 15665468
[TBL] [Abstract][Full Text] [Related]
17. [Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy].
Zhang Y; Ma H; Liu SL; Liu YX; Zheng DX
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(7):475-9. PubMed ID: 18642790
[TBL] [Abstract][Full Text] [Related]
18. Targeting gene expression of the mouse uroplakin II promoter to human bladder cells.
Zhu H; Zhang ZA; Xu C; Huang G; Zeng X; Wei S; Zhang Z; Guo Y
Urol Res; 2003 Mar; 31(1):17-21. PubMed ID: 12624658
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific, hypoxia-regulated, WW domain-containing oxidoreductase-expressing adenovirus inhibits human non-small cell lung cancer growth in vivo.
Zhang P; Ying L; Xu R; Ge S; Mei W; Li F; Dai B; Lu J; Qian G
Hum Gene Ther; 2010 Jan; 21(1):27-39. PubMed ID: 19737107
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.
Takeda T; Inaba H; Yamazaki M; Kyo S; Miyamoto T; Suzuki S; Ehara T; Kakizawa T; Hara M; DeGroot LJ; Hashizume K
J Clin Endocrinol Metab; 2003 Aug; 88(8):3531-8. PubMed ID: 12915632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
